BKI-1369

立即咨询

BKI-1369

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1951431-22-3

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品介绍

BKI-1369 是一种 bumped kinase 抑制剂 (BKI)。 BKI-1369 增加人类 Ether-a-go-go-related 相关基因 (hERG) 的抑制活性，IC50 为 1.52 μM。BKI-13699 降低了生殖猪模型中的寄生虫负担和疾病严重程度。BKI-1369 已经充分表征了效力，稳定性，代谢，毒性和药代动力学，并且可以有效抑制感染的小鼠和小牛中的微小隐孢子虫 (C. parvum)。

Cas No.	1951431-22-3
Canonical SMILES	NC1=C2C(N(CC3CCN(C)CC3)N=C2C4=CC=C5N=C(OCC)C=CC5=C4)=NC=N1
分子式	C₂₃H₂₇N₇O
分子量	417.51
溶解度	DMSO: 50 mg/mL (119.76 mM)
储存条件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
产品描述	BKI-1369 is a bumped kinase inhibitor (BKI). BKI-1369 increases human Ether-a-go-go-related gene (hERG)-inhibitory activity with an IC50 of 1.52 μM. BKI-1369 reduces the parasite burden and diseases severity in the gnotobiotic pig model. BKI-1369 has been well characterized for potency, stability, metabolism, toxicity, pharmacokinetics and is potent against C. parvum in infected mice and calves[1]. IC50: 1.52 μM (hERG)[1] [1]. Lee S, et al. Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by Cryptosporidium hominis. Antimicrob Agents Chemother. 2018 Jun 26;62(7).